ANKRD29

Across TCGA pan-cancer cohorts, ANKRD29 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD29 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ANKRD29 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD29 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, GBM, and HNSC are the cancer types where ANKRD29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.854	0.331	.034	3	view →
GBM	OS	Tertile	All	0.518	0.259	.019	3	view →
HNSC	OS	Tertile	All	1.000	0.644	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANKRD29–LSCC (DFS)

Open the LSCC breakdown →